Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
Takayuki Takahama(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 72
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
|Annals of Oncology|2017|294
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
|Clinical Cancer Research|2018|169